-+ 0.00%
-+ 0.00%
-+ 0.00%
Maia Biotechnology wins $2.3 million NIH grant for Phase 2 NSCLC trial expansion
Share
Listen to the news
Maia Biotechnology wins $2.3 million NIH grant for Phase 2 NSCLC trial expansion
  • Maia Biotechnology secured FDA clearance for an amended IND for ateganosine, citing improved manufacturing capabilities and efficiencies.
  • The NIH awarded Maia a USD 2.3 million grant to fund a U.S. Phase 2 expansion in third-line non-small cell lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160815PRIMZONEFULLFEED9827717) on September 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending